Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health is a strong investment opportunity as it has recently launched Befrena, a new derm product with great potential to take market share from the only other competitor in the market. They have also reported strong financials, with a 4.2% beat on total revenue in the second quarter, increased guidance for the third quarter and full year, and plans to accelerate price taking in the second half. Additionally, the company has an impressive innovation pipeline with seven potential blockbuster launches that will contribute to sales growth and margin expansion.

Bears say

Elanco Animal Health is facing intense competition in the animal health market and is being forced to compete through portfolio selling and targeted marketing rather than price. It has recently seen a decline in sales due to competition, and its strategy to accelerate price taking in the second half of 2026 may not be successful as it relies on targeted advertising. Additionally, while the company has a strong pipeline of innovative products, there is uncertainty surrounding their commercial success, which could lead to potential losses in revenue.

ELAN has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 9 analysts, ELAN has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.